DOCSLIB.ORG

Master of $I)Ilof(Opl)P in 2Oolosp

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Master of $I)Ilof(Opl)P in 2Oolosp BIOCHEMICAL AND CYTOGENETIC EFFECTS OF ORAL CONTRACEPTIVES AMONG WOMEN DISSERTATION SUBMITTED IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE AWARD OF THE DEGREE OF /^ Master of $I)ilof(opl)p in 2oolosp w By FALAQ NAZ o^ssf^^^-^''^io*--* ^ Under the Supervision of DR. YASIR HASAN SIDDIQUE SECTION OF GENETICS DEPARTMENT OF ZOOLOGY ALIGARH MUSLIM UNIVERSITY ALIGARH 2014 A iSyo sP:^ ^ <30 2 4 ;.CV 2014 DS4398 DROSOPHILA TRANSGENIC Dr. Yasir Hasan Siddique RESEARCH LABORATORY (Assistant Professor) E-mail: [email protected] CERTinCATE Certified that the thesis entitled ^Biochemical and Cytogenetic Effects of Oral Contraceptives among Women'' by Ms. Falaq naz for the partial fulfillment of the degree of Master of Philosophy (Zoology, Genetics) of the Aligarh Muslim University f Aligarh. The subject matter of dissertation as presented by Ms. Falaq Naz is the actual record of work done by her under my supen^sion and guidance, and the same does not form the part of any other course or degree presented to or taken by her. Dr./Yasir./Yasir Hasan SiSiddiquc e (Supervisor) Section of Genetics, Department of Zoology Aligarh Muslim University, Aligarh-202002, U.P., India DEDICATION TO THE LOVEUEST PARENTS IN THE WORLD WHO SUPPORT ME WITH AU. THEIR . HEARTS I? ' ^ TO TO MV DEAREST FRIENDS FOR THEIR h SUPPORT AND DUA IN HARD CIRCUMSTANCES TO MV UNIVERSITY WHICH IS WORKING TO IMPROVE THE RESEARCH TABLE OF COOTEFTS ACKNOWLEDGEMENTS 1-11 UST OF TABLES iii UST OF FIGURES iv ABBREVIATIONS v-vi 1. GENERAL INTRODUCTION 1-22 1.1. Female reproductive cycle 1 1.2. History of oral contraceptives 4 1.2.1. Oral contraceptives 7 1.2.2. Combined oral contraceptives 7 1.2.3. Progestin only oral contraceptives 9 1.2.4. Pharmacological classification 10 1.3. Mechanism of action of oral contraceptives 11 1.4. Scenario in India and abroad 13 1.5. Blood serum markers 14 1.5.1. Serum Enzymes 14 1.5.1.1. Alkaline phosphatase 14 1.5.1.2. Gamma glutamyl transferase 14 1.5.1.3. Amino transferases 15 1.5.1.4. Lactate dehydrogenase 16 1.5.2. Lipid profile 17 1.5.2.1. Total Cholesterol (PC) 17 1.5.2.2. High Density Lipoprotein Cholesterol (HDL-C) 17 1.5.2.3. Low Density Lipoprotein Cholesterol (LDL-C) 18 1.5.2.4. Triglycerides (PC) 19 1.5.3. Genotoxicity tests 20 1.5.3.1. Chromosomal aberration, Sister chromatid exchanges, DNA 20 fragmentation 1.5.3.2. Comet assay or Single cell gel electrophoresis assay 21 2. REVIEW OF UTERATURE 23-36 3. GENOTOXIC DAMAGE IN CULTURED HUMAN 37-43 PERIPHERAL BLOOD LVMPHOCVTES OF ORAL CONTRACEPTIVE USERS 3.1. Introduction 37 3.2. Materials and Methods 37 3.2.1. Chemicals 37 3.2.2. Human lymphocyte culture 37 3.2.3. Chromosomal aberration analysis 38 3.2.4. Sister chromatid exchanges 38 3.2.5. Quantitative assay for DNA fragmentation 39 3.2.6. Statistical analysis 39 3.3. Results and Discussion 39 3.4. Conclusion 43 4. UPID PROFILE Of WOMEN USING ORAL 45-51 CONTRACEPTIVE PILLS 4.1. Introduction 45 4.2. Materials and Methods 46 4.2.1. Sample Size 46 4.2.2. Blood sampling and processing 46 4.2.3. Blood parameters 46 4.2.4. Lipidprofile 46 4.2.5. Statistical analysis 48 4.3. Results and Discussion 48 4.4. Conclusion 50-51 EFFECT OF ORAL CONTRACEPTIVE PILLS ON THE 53-65 BLOOD SERUM ENZVMES AND DNA DAMAGE IN LVMPHOCVTES AMONG USERS 5.1. Introduction 53 5.2. Material and Methods 53 5.2.1. Sample size 53 5.2.2. Blood sampling and processing 54 5.2.3. Blood serum analysis 54 5.2.4. Enzyme profile 54 5.2.5. Single cell gel electrophoresis (SCGE) 56 5.2.5.1. Blood sampling for comet assay 56 5.2.5.2. Slide preparation and Electrophoresis 56 5.2.5.3. Staining 57 5.2.5.4. Slide scoring 57 5.2.6. Statistical analysis 57 5.3. Results and Discussion 58 5.4. Conclusion 64 6. BIBUOQRAPHY 67-93 ACKNOlfLEDaEMENTS Praise be to Allah, the lord of the worlds, who says in his glorious book, "There has come to you from Allah a light and a plain book" and peace and blessing of Allah be upon the noblest of the prophets and messengers, our Prophet Mohammad who has said, "you should insist on acquiring knowledge even if you have to travel up to China. " And "seek knowledge from cradle to grave. " In the name of Almighty Allah, who favored me to achieve this work I thought unattainable. To whom belong might and majesty, I bring all the praises and commendation for providing me with strength during the work of my research which helped me to overcome the troubles and difficulties in the toilsome journey and who well fixed me whenever I declined in vigor or vitality. Praise is to him. I feel deeply obliged to express my profound gratitude to my esteemed supervisor Dr. Yasir Hasan Siddique, Department of Zoology, Aligarh Muslim University, Aligarh for his scholastic guidance, persistence inspiration, and vital encouragement throughout the course of this research work. His predicted advices as a think tanker, imagination towards the target help have been invaluable at every stage of this work. He has indeed been a source of inspiration to me. I will always remain thankful to him. I would like to express my thanks and gratitude to Dr. (Mrs.) Nishat Akhtar, Department of Obstetrics and Gynaecology, Jawahar lal Nehru Medical College, Aligarh Muslim University, Aligarh for her consistent help and guidance and help me in drawing the blood sample from the women in my research tenure. Her guidance rendered to me with a dedication far beyond the call of any duty. At this juncture of my life I wish to thank my beloved parents and my brother Mr. Abdul Sheeraz, and my dearest friends Ms. Mahino Fatimafor their inspiration and the innumerable sacrifices, the unmatched love, sincerity and for encouraging me to accomplish this task and provided me the self-confidence. The biggest and unforgettable thanks belong to Professor (Dr.) Mohammad Afzal who gives sound advice and numerous fruitful discussions regarding fundamental of research and Dr. (Mrs.) Gulshan Arafor their cheerful and helping moment. I sincerely thank to her suggestions from time to time that helped me to explore innovativeness and tackling the experimental difficulties. She always willingly spared much of her precious time to discuss my problems. Words are inadequate to express my indebtedness to her, who made this intricate and difficult work, easy and fruitful to me. / would like to express my special appreciation for my lab colleague Ms. Smita Jyoti, Mr. Rahul, Mr. Fahad AH, Ms. Ambreen Fatima and Ms. Saba Khanam, for their sound advice, good company, long drive and fruitful discussions and of course to the wonderful moments we had together. I will always remain thankful to Mahino Fatima, Shagufi Fatima, Nabila Abbas, Mr. Kamal Hussain, Ms. Huma Haider, Mr. Irfanullah Siddique, Mr. Rahul, for being my financial strength through all this long process no matter at what time or day of the week to making this journey of mine as stress free as possible. Life is incomplete without friends. I am so privileged to have friends like Vignesh Venkataswamy, Sharad Behal, Barkha Shakya, Vibhor Singh, Rafi Alam, Krishna Kumar, Sakshi Saxena, Yusra Zaidi, Areeba Ahmad, Nazia Nazam, Umme Asma, Salman Khalil, Friyanka Gaur, Abu Hussain, Rashid Nayeem, Nazia Kamal, Afzal Khan, Ahsana Shah, Rashmi Medhavifor always inspiring me to step ahead to achieve my goals and taught me to smile in every circumstances. I would like to thanks my seniors Dr. Subuhi Abidi, Dr. Zeba Khan, Ms. Ruqaiyya Hussain, Dr. Jyoti Gupta, Dr. Nuzhat Perveen, Iram Khan, for their constant encouragement with prayers and support. I would like to thank Chairman Professor (Dr.) Iqbal Pervez, Department of Zoology, Aligarh Muslim University, for the facilities provided to me by the department during my study. I was very fortunate to be in contact with Professor (Dr.) Waseem Ahmad Faridi, Professor (Dr.) Irfan Ahmad and (Dr.) Nazura Usmani. My special thanks to University Grant Commission (UGC), New Delhi for the award of project entitled: "Biochemical and Cytogenetic effects of Oral Contraceptives among women of different reproductive histories" fF.No. 39-582/2010(SR)J to Dr. Yasir Hasan Siddique, Department of Zoology, Aligarh Muslim University, Aligarh in which I worked as project fellow and take financial support for my work. FftLAQ NAZ UST OF TABLES Table-2.1. Studies carried out on biochemical and DNA damaging effects of oral 27-36 contraceptives. Table-3.L Chromosomal aberration in cultured human peripheral blood lymphocytes of 42 (OC) users and non-users (control). Table-3.2. Distribution of Sister chromatid exchanges (SCEs) among women using oral 43 contraceptives (OCs). Table-3.3. Estimation of DNA damage among Oral contraceptives (OCs) users and non- 43 users. Table- 4.1. Lipid profile of oral contraceptive (OC) users and non-users women. 50 TabIe-5.1. Age distribution of oral contraceptives non-users and users. 57 TabIe-5.2, Distribution of users on the basis of using oral contraceptives. 57 Table-5.3. Oral contraceptive formulations used by Women. 57 TabIe-5.4. Enzyme profile in the blood serum of oral contraceptive users and non users 58 in different age groups Tabie-5.5. Enzyme profile in blood serum on the basis of duration (months) of using 59 oral contraceptives. Ill UST OF FIGURES Figure-1.1. Figure shows the different parts of the human female genital 3 tract.
Load more

Recommended publications
  • Schwangerschaften Während Der Anwendung Kontrazeptiver Methoden
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie Schwangerschaften während der Anwendung kontrazeptiver Methoden - Eine Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V. und des Berufsverbands der Frauenärzte (BVF) e.V. Rabe T, Goeckenjan M, Dikow N, Schaefer C, Ahrendt HJ Mueck AO, Merkle E, Merki G, Egarter C, König K Albring C J. Reproduktionsmed. Endokrinol 2013; 10 (4), 214-234 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Schwangerschaften während der Anwendung kontrazeptiver Methoden Schwangerschaften während der Anwendung kontrazeptiver Methoden* Eine Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V.
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
    Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Early Release May 28, 2010 / Vol. 59 U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition department of health and human services Centers for Disease Control and Prevention Early Release CONTENTS The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Introduction .............................................................................. 1 Disease Control and Prevention (CDC), U.S. Department of Health Methods ................................................................................... 2 and Human Services, Atlanta, GA 30333. How to Use This Document ......................................................... 3 Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR Early Release 2010;59[Date]:[inclusive page numbers]. Using the Categories in Practice ............................................... 3 Recommendations for Use of Contraceptive Methods ................. 4 Centers for Disease Control and Prevention Contraceptive Method Choice .................................................. 4 Thomas R. Frieden, MD, MPH Director Contraceptive Method Effectiveness .......................................... 4 Peter A. Briss, MD, MPH Unintended Pregnancy and Increased Health Risk ..................... 4 Acting Associate Director for Science Keeping Guidance Up to Date ...................................................
    [Show full text]
  • Steroids – Basic Science
    STEROIDS – BASIC SCIENCE Edited by Hassan Abduljabbar Steroids – Basic Science Edited by Hassan Abduljabbar Published by InTech Janeza Trdine 9, 51000 Rijeka, Croatia Copyright © 2011 InTech All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. As for readers, this license allows users to download, copy and build upon published chapters even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Publishing Process Manager Bojan Rafaj Technical Editor Teodora Smiljanic Cover Designer InTech Design Team Image Copyright loriklaszlo, 2011. DepositPhotos First published December, 2011 Printed in Croatia A free online edition of this book is available at www.intechopen.com Additional hard copies can be obtained from [email protected] Steroids – Basic Science, Edited by Hassan Abduljabbar p.
    [Show full text]
  • Endocrine Dynamic Function Protocols
    South Eastern Area Laboratory Services DEPARTMENT OF CLINICAL CHEMISTRY & ENDOCRINOLOGY SEALS Pathology Service Randwick Campus Dynamic Function Protocol DETAILS OF TESTS AVAILABLE AND SPECIMENS REQUIRED Compiled by: Phoebe Stanford Registrar Dept of Clinical Chemistry and Endocrinology SEALS North South Eastern Area Laboratory Services SEALS PATHOLOGY SERVICE RANDWICK CAMPUS TABLE OF CONTENTS PATIENT PREPARATION……………………………………………………….. 4 PROCEDURE FOR USING THE GLUCOMETER…………………………….. 6 PANCREAS DIABETES GLUCOSE TOLERANCE TEST …………………………………………………………………………..7 GESTATIONAL DIABETES SCREENING………………………………………………………………..8 GTT FOR INSULIN RESISTANCE (PCOS)…………………………………………………………….10 MEAL TOLERANCE……………………………………………………………………………………….10 EXTENDED GLUCOSE TOLERANCE TEST……………………………………………………11 ANTERIOR PITUITARY ANTERIOR PITUITARY FUNCTION ITT………………………………………………………………………………………………..12 CUSHING'S DISEASE OVERNIGHT DEXAMETHASONE TEST……………………………………………………15 BILATERAL SIMULTANEOUS INFERIOR PETROSAL SINUS SAMPLING…………….16 ACROMEGALY GROWTH HORMONE SUPPRESSION TEST (OGTT) FOR ACROMEGALY……………26 POSTERIOR PITUITARY DIABETES INSIPIDUS WATER DEPRIVATION TEST………………………………………………………………..27 ADRENAL ADRENAL INSUFFICIENCY SHORT SYNACTHEN TEST…………………………………………………………………..30 SYNACTHEN TEST - CONGENITAL ADRENAL HYERPLASIA………………………….32 HYPERALDOSTERONISM SALINE SUPPRESSION TEST………………………………………………………………..33 LYING/STANDING AND FRUSEMIDE TEST………………………………………………..34 ADRENAL VENOUS SAMPLING……………………………………………………………..36 CHEMAI - Dynamic Function Protocol - 05 Page 2 of 47 Authorised by:
    [Show full text]
  • MEC Fourth Edition Spread
    Critères de recevabilité pour l'adoption et l'utilisation continue de méthodes contraceptives CHC Méthode de l’aménorrhée lactationnelle Stérilisation chirurgicale féminine Progestatifs seuls DIU Pilules pour la contraception d’urgence DIU Méthodes mécaniques Contraceptifs hormonaux combinés CHC Méthodes naturelles de planification familiale Coït interrompu StérilisationQuatrième chirurgicalegica édition, 2009 CHC Méthode de l’aménorrhée lactationnelle StérilisationGUIDE c ESSENTIELhirurgicale OMS DE PLANIFICATION FAMILIALE féminine Progestatifs seuls DIU Pilules pour la contraception d’urgence DIU Méthodes mécaniques Contraceptifs hormonaux combinés CHC Méthodes naturelles de planification familiale Coït interrompu Stérilisation chirurgicale CHC Méthode de l’aménorrhée lactationnelle Stérilisation chirurgicale féminine Progestatifs seuls DIU Pilules pour la contraception d’urgence DIU Méthodes mécaniques Contraceptifs hormonaux combinés CHC Méthodes naturelles de planification familiale Coït interrompu Stérilisation chirurgicale CHC Méthode de l’aménorrhée lactationnelle Stérilisation chirurgicale féminine Progestatifs seuls DIU Pilules pour la contraception d’urgence DIU Méthodes mécaniques Contraceptifs hormonaux combinés CHC Méthodes naturelles de planification familiale Coït interrompu Stérilisation chirurgicale Catalogage à la source: Bibliothèque de l’OMS: Critères de recevabilité pour l’adoption et l’utilisation continue de méthodes contraceptives -- 4e éd. 1.Contraception - méthodes. 2.Services de planification familiale. 3.Détermination
    [Show full text]
  • For Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies
    Rapid and Sensitive Enzyme-Linked Immunosorbent Assays (ELISAs) for Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies Chatchaporn Uraipong Thesis submitted in partial fulfillment of the requirement for the Degree of Master of Science (Research) School of Chemical Engineering The University of New South Wales September, 2010 ABSTRACT Endocrine disrupting chemicals (EDCs) are chemicals that alter functions of the endocrine system and cause health effects in an intact organism, or progeny, or population, with reproductive, developmental, or carcinogenic consequences. In order to facilitate risk assessment of potential endocrine disrupting steroids that are present in ultra low concentrations in the Australian environment, there is a need to boost the analytical capacity for EDC detection. One strategy is to develop antibody-based techniques that can offer simple, cost-effective and reliable analysis with high throughput capacity and portability for real-time monitoring. This thesis describes the design and synthesis of hapten molecules, raising of specific antibodies, formatting and characterising of a series of sensitive competitive Enzyme-Linked Immunosorbent Assays (ELISAs) for 17β-estradiol (E2), 17α-ethynylestradiol (EE2), ethylestradiol-3-methyl ether (mestranol) and testosterone (T), including validation of their performance as fast and effective water monitoring tools. Application of the developed assays to investigate the levels of the target EDCs in bodies of water and efficiency of water treatment plants in urban and rural areas in New South Wales, Australia, is also discussed. 17α-Ethynylestradiol and related synthetic estrogens, are active ingredients of contraceptive pills and hormone therapy, and have been identified as potent EDCs (Warner and Jenkins, 2007).
    [Show full text]
  • Norethisterone and Ethinylestradiol
    26 April 2019 EMA/245512/2019 - corr 1 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation (EC) No 726/2004 Norethisterone and ethinylestradiol Procedure number: EMEA/H/A-5(3)/1477 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction ...................................................................................................... 3 2.2. Assessment of the meta-analysis .......................................................................... 4 2.3. Discussion of the meta-analysis ......................................................................... 25 3. Overall Conclusions ............................................................................... 28 4. References ...........................................................................................
    [Show full text]
  • Identification of Unknown Residues
    Project number: 871.639.01 BAS-code: WOT-02-438-III-036 Project title: Identification of unknown residues Project leader: R.J.B. Peters Report 2009.013 November 2009 Identification of Unknown Residues using bioassay directed fractionation, UPLC/TOFMS analysis and database searching R.J.B. Peters, J.C.W. Rijk, J.E. Oosterink, A.W.J.M. Nijrolder and M.W.F. Nielen Business Unit: Veterinary Drugs Group: Analytical Services & Development RIKILT - Institute of Food Safety Wageningen University and Research Centre Akkermaalsbos 2, 6708 WB Wageningen, The Netherlands P.O. Box 230, 6700 AE Wageningen, The Netherlands Tel +31 317 480 256 Fax +31 317 417 717 Internet www.rikilt.wur.nl Copyright 2009, RIKILT – Institute of Food Safety. The client is allowed to publish or distribute the full report to third parties. Without prior written permission from RIKILT – Institute of Food Safety it is not allowed to: a) publish parts of this report; b) use this report or title of this report in conducting legal procedures, for advertising, acquisition or other commercial purposes; c) use the name of RIKILT – Institute of Food Safety other than as author of this report. The research described in this report was funded by the Dutch Ministry of Agriculture, Nature and Food Quality (WOT-02-438-III-036) Distribution list: • Food and Consumer Product Safety Authority (VWA); J.A. van Rhijn • National Institute for Public Health and the Environment (RIVM); drs. M. Blokland, dr. L. van Ginkel, drs. S.S. Sterk This report from RIKILT - Institute of Food Safety has been produced with the utmost care.
    [Show full text]
  • Transgender Adults, Gender-Affirming Hormone Therapy and Blood Pressure: a Review Systematic
    View metadata, citation andReview similar papers at core.ac.uk brought to you by CORE provided by Enlighten Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review Paul J. Connelly, Anna Clark, Rhian M. Touyz, and Christian Delles estrogen, gonadotropin-releasing hormone (GnRH) ana- Objectives: Gender-affirming hormone therapy (GHT) is 04/14/2021 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= by http://journals.lww.com/jhypertension from Downloaded logues and antiandrogens, aims to align the characteristics utilized by people who are transgender to align their of transgender people with their gender identity [1]. Downloaded secondary sex characteristics with their gender identity. The recent substantive increases in population preva- Data relating to cardiovascular outcomes in this population lence of transgender people requires the implementation of are limited. We aimed to review the impact of GHT on the from evidence-based guidance to better protect the health of this http://journals.lww.com/jhypertension blood pressure (BP) of transgender individuals. population [2–4]. However, due to a paucity of epidemio- Methods: We searched PubMed/MEDLINE, SCOPUS and logical and mechanistic data, there is considerable uncer- Cochrane Library databases for articles published relating tainty surrounding the impact of GHT on the cardiovascular to the BP of transgender adults commencing GHT. health of transgender individuals [5–7]. Existing data sug-
    [Show full text]
  • United States Patent Office Patenied Feb
    3,076,829 United States Patent Office Patenied Feb. 5, 1963 rez 2 3,976,829 are the alkali metal salts of the dibasic carboxylic acid NOVEL 9,1-EDISUBSTITUTED ESTRATRENE esters such as, for example, the 3,17-di-sodium hemisuc DERWATWES cinate of 9oz-chloro-11-ketoestradiol. Haas Reinaan, Bloomfield, and Cecil H. Robinson, Cedar The above -definition of the novel compounds of our Grove, N.J., assignors to Schering Corporation, Bloom 5 invention should not be strictly construed but rather field, N.J., a corporation of New Yersey may be considered to admit the presence of other sub No Drawing. Fied Sept. 15, 1961, Ser. No. 138,271 stituents on the steroid nucleus, particularly at positions 29 Cairns. (CI. 269-397.45) 6 and 16, Such as 60-methyl, 60-fluoro, 6a-chloro, 16cy hydroxy, 160-acyloxy, 16-methyl and 16-halogen analogs This invention is concerned with novel, therapeutical O thereof. This modification depends solely on the choice ly active 9,11-disubstituted estrogens and methods for of starting material employed, which in the instant case their manufacture. More specifically, this invention re would involve the employment of a 9(11)-dehydro lates to novel 9a, 11,3-disubstituted-1,3,5(10)-estratrienes estratriene Starting steroid possessing the desired sub and analogs thereof, which possess estrogenic activity. stituent in the positions indicated, which substituents are Included among the novel estratrienes of our invention 5 introduced by methods known in the art. are compounds having the following structural formula: The novel estratrienes defined by the general formula CH possess estrogenic activity and thus are therapeutically Z.
    [Show full text]
  • Differential Effects of Estrone and Estrone-3-O-Sulfamate Derivatives on Mitotic Arrest, Apoptosis, and Microtubule Assembly in Human Breast Cancer Cells1
    [CANCER RESEARCH 60, 5441–5450, October 1, 2000] Differential Effects of Estrone and Estrone-3-O-Sulfamate Derivatives on Mitotic Arrest, Apoptosis, and Microtubule Assembly in Human Breast Cancer Cells1 Lucy MacCarthy-Morrogh, Paul A. Townsend, Atul Purohit, Hatem A. M. Hejaz, Barry V. L. Potter, Michael J. Reed, and Graham Packham2 Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial College School of Medicine, St. Mary’s Hospital, London W2 1NY [L. M-M., A. P., M. J. R.]; CRC Wessex Medical Oncology Unit, Southampton General Hospital, Southampton SO16 6YD [P. A. T., G. P.]; Wolfson Laboratory of Medicinal Chemistry and Sterix Ltd., Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY [H. A. M. H., B. V. L. P.]; and Ludwig Institute for Cancer Research [L. M-M., G. P.], Virology and Cell Biology, Department of Medical Microbiology [P. A. T., G. P.], Imperial College School of Medicine, St. Mary’s Campus, London W2 1PG, United Kingdom ABSTRACT 2-MeOE2 inhibits the growth of many cells, including human breast cancer lines, in vitro (3), and oral administration of 2-MeOE2 There is considerable interest in the potential use of estrogen deriva- inhibits the growth of transplanted Meth-A sarcoma and B16 mela- tives for the treatment and prevention of breast cancer. We demonstrated noma in C3H mice (4) and human MDA-MB-453 breast carcinoma previously that the sulfamoylated estrone derivative 2-methoxyestrone-3- cells in immunodeficient mice (5). 2-MeOE2 induces a reversible O-sulfamate (2-MeOEMATE) induced G2-M cell cycle arrest and modest levels of apoptosis in breast cancer cells in vitro, whereas the parent mitotic arrest (6) and apoptosis in retinoic acid-differentiated neuro- estrone derivative, 2-methoxyestrone, did not.
    [Show full text]
  • Use of Oral Contraceptives and Serum Beta-Carotene
    European Journal of Clinical Nutrition (1997) 51, 181±187 ß 1997 Stockton Press. All rights reserved 0954±3007/97 $12.00 Use of oral contraceptives and serum beta-carotene G Berg1, L Kohlmeier2 and H Brenner1 1Department of Epidemiology, University of Ulm, Albert-Einstein-Allee 43, 89069 Ulm, Germany and 2Department of Nutrition, University of North Carolina, Chapel Hill, NC 27514, USA Objective: Antioxidants, in particular carotenoids, may in¯uence the risk for cardiovascular disease. This study investigates the in¯uence of oral contraceptives (OC) on the serum concentration of beta-carotene, which may in turn affect the risk of cardiovascular diseases due to its antioxidative impact. Design: Cross-sectional epidemiologic study. Examinations included a detailed questionnaire on medical history and lifestyle factors, a 7 day food record, and blood samples. Setting: National health and nutrition survey among healthy people living in private homes in West Germany in 1987±1988. Subjects: Nonpregnant and nonlactating women aged 18±44 (n 610). Results: Overall, the use of OC was negatively associated with serum beta-carotene concentration in bi- and multivariable analyses after adjustment for age, smoking, alcohol consumption, dietary intake of beta-carotene, use of vitamin supplements, body mass index, pregnancies, and serum concentrations of total triglyceride and cholesterol. A strong interaction between OC use and age on beta-carotene concentration was observed. While no relationship between OC use and serum beta-carotene was seen in the youngest age-group (18±24 y), there was a modest but signi®cant negative association between OC use and beta-carotene levels among 25±34 y old women.
    [Show full text]